1Tredaniel J,Becht C, Bekradda M, et al. An open phase Ⅱ trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients [ J ]. Lung Cancer, 2009, 63 (2) : 259 - 263.
2Gunnlaugsson A,Anderson H, Fernebro E, et al. Multicentre phase Ⅱ trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study [ J ]. Eur J Cancer, 2009, 45(5) : 807 -813.
4Wenzel J,Zeisig R, Iduna . Fichtner Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation[J]. Int J Pharm, 2009, 370(1/2): 121- 128.
5Suzuki R,Takizawa T, KuwataY, et al. Effective antitumor activity of oxaliplatin encapsulated in transferrin- PEG-liposome[ J]. Int J Pharm, 2008, 346(1/2) : 143 - 150.
6Furuhata M, Izumisawa T, Kawakami H, et al. Decaarginine-PEG-liposome enhanced transfeetion efficiency and function of arginine length and PEG [ J ]. Int J Pharm, 2009, 371 (1/2): 40-46.
7Ishida T, Shiraga E, Kiwada H, et al. Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model [ J ]. J Controlled Release, 2009, 134(3) : 194 -200.
8Ito Y,Kimura Y, Shimahara T, et al. Disposition of TFPEG-liposome-BSH in tumor-bearing mice[ J]. Appl Radiat Isot,2009, 67(7/8) : 109 - 110.
9Kobayashi T, Ishida T, Okada Y, et al. Effect of transferrin receptor targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells [ J ]. Int J Pharm, 2007, 329(1/2) : 94- 102.
